Article Text

Download PDFPDF

418 First real-world hematologic adverse events experience with niraparib in advanced ovarian cancer
  1. Junjian Wang and
  2. Jianqing Zhu
  1. Cancer Hospital of the University of Chinese Academy of Sciences (zhejiang Cancer Hospital)


Introduction/Background Niraparib, a poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor, has been approved by Food and Drug Administration (FDA) for ≥3 line recurrence ovarian cancer (OC), the platinum-sensitive recurrence maintenance treatment and new diagnosed maintenance treatment using individual starting dose (ISD, 200 mg daily for body weight <77 kg or platelet count <150,000/μL, 300 mg daily for body weight ≥77 kg and ≥150,000/μL). This study aimed to retrospectively assess the incidence of hematologic adverse events (AEs) in real-world Chinese OC patients using ISD niraparib in Zhejiang Cancer Hospital.

Methodology All medical records of OC patients with ISD niraparib in the Zhejiang Cancer Hospital from February 2019 to January 2020 were reviewed. Treatment-emergent hematologic AEs including leukopenia, anemia and thrombocytopenia were collected and analyzed.

Results A total of 43 patients with OC were included in this study. The median body weight was 50.5 (33, 75) kg. 200 mg QD was taken as ISD for all patients. Twenty seven (62.8%) patients were of BRCA wild-type, 14 (32.6%) were of BRCA mutants and 2 (4.6%) were unknown. Niraparib was used as newly diagnosed maintenance treatment in 25 (58.1%) patients, as treatment for ≥3 line recurrence treatment in 14 (32.6%) patients, and as platinum-sensitive recurrent maintenance treatment in 4 (9.3%) patients. Overall, 28 (65.1%) patients experienced ≥1 grade hematologic AEs, which included leukopenia (37.2%), anemia (34.9%) and thrombocytopenia (39.5%). Only 10 (23.3%) patients had grade 3/4 AEs including leukopenia (9.3%), anemia (7.0%) and thrombocytopenia (11.6%). Until last follow up, the median time for the occurrence of leukopenia, anemia and thrombocytopenia were 30 (range: 7, 162), 34 (range: 7, 108) and 20 (range: 13, 180) days, respectively. No deaths were reported. Of those patients who experienced AEs during treatment, the dose was reduced in 4 (14.3%) patients, and treatment was interrupted in 9 (32.1%) patients. Additional recombinant human granulocyte colony stimulating factor (n=5, 17.9%), erythrocyte (n=2, 7.1%) and recombinant human thrombopoietin (n=5, 17.9%) were provided for treating the AEs. After intervention, 8 (18.6%) patients restart the treatment and only 1 (2.3%) patient discontinued the treatment.

Conclusion The incidence of hematologic AEs in real-world experience was lower than reported by niraparib 300 mg/day in ENGOT-OV16/NOVA trial. In addition to maintenance treatment in the first line, the patients in platinum-sensitive recurrence treatment and later line treatment might benefit from ISD niraparib.

Disclosures The authors declare that they have no competing interests.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.